Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of intra-inguinal lymph node GAD-alum injections in LADA
2019-002692-34Phase 2Completed
- Sponsor
- NTNU
- Start
- Aug 2019
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Diamyd in latent autoimmune diabetes in adults (LADA), sponsored by NTNU. Primary endpoint: Safety and feasibility endpoints. Started Aug 2019; status: completed.
02
Drugs
Diamyd
03
Conditions
latent autoimmune diabetes in adults (LADA)
Beyond the preview
Go deeper on 2019-002692-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002692-34.